Đặc điểm lâm sàng, cận lâm sàng và xác định tình trạng đột biến EGFR-T790M gây kháng EGFR-TKIs thế hệ thứ nhất ở người bệnh ung thư phổi không tế bào nhỏ bằng kỹ thuật sinh thiết lỏng

To investigate clinical and laboratory characteristics to determine the status of EGFR-T790M mutations causing first-generation resistance to EGFR-TKIs in patients with non-small cell lung cancer by liquid biopsy technique. Subjects: Including 31 patients diagnosed with EGFR-mutated non-small cell lung cancer (+) who received first-step treatment with first-generation EGFR-TKIs, and had liquid biopsies for EGFR-T790M mutations. Result: The study patients were mainly over 60 years old (64.5%) in which the male: female ratio was approximately equal; up to 58.1% of the patients did not smoke. The mean time of emergence of resistance to 1st generation TKIs: 11.9 ± 3.4 months (ranged from 7-20 months). Fatigue (96.8%) and weight loss (87.1%) were systemic symptoms accounting for the highest proportion. Chest pain (77.4%) was the most common respiratory symptom; hemoptysis (12.9%) was the least common. The number of patients with tumor sizes from 2-3cm is the highest, accounting for 32.3%, up to 9.7% of patients with tumor size >7cm. EGFR-T790M mutations detected by liquid biopsy method was 35.5%; up to 64.5% of patients had advanced disease, but liquid biopsy results did not have EGFR-T790M gene mutations. Median progression-free survival between the group carrying the EGFR-T790M mutation (11.82 months; 95% CI 9.22-14.42) and the group not carrying the EGFR-T790M mutation (11.95 months); 95%CI 10.44-13.46) there was no statistically significant difference.